BioSig Technologies this week announced it signed a master research agreement with the Cleveland Clinic to explore expanded indications for digital signal processing in arrhythmia care.
The Westport, Connecticut-based company will sponsor a research agreement with the Cleveland Clinic Foundation to investigate expanded clinical applications for the intracardiac signals that are acquired by its Pure EP system. Through the agreement, Cleveland Clinic will conduct physician-initiated scientific research investigating Pure EP potential to address common limitations of signal processing and signal use expansion during electrophysiology ablation procedures.
Cleveland Clinic was selected as the research partner based on its world-class physician faculty, research competency and mutual interest in using digital signal processing technology to advance the field of cardiac electrophysiology.
“As a non-profit, research, education, and healthcare institution, Clevel…